The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prospective “common arm” comparison of US SWOG S0424 and Japanese JME studies in early-stage non-small cell lung cancer (NSCLC): Survival differences in the context of race, gender and smoking.
 
Philip C. Mack
Honoraria - Abbvie
Consulting or Advisory Role - Amgen; Guardant Health; Vivace Therapeutics
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim; Genentech (Inst)
 
Shun-ichi Isa
No Relationships to Disclose
 
Ming-Hui Hsieh
No Relationships to Disclose
 
Yasuhiro Koh
Honoraria - Amgen; Chugai Pharma; Cytogen; Guardant Health; Novartis; Tosoh Corporation
Consulting or Advisory Role - Tosoh Corporation
Research Funding - Amgen; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Takeda (Inst); Tosoh Corporation; Zeon Corporation
 
James Moon
No Relationships to Disclose
 
Akihiro Tamiya
No Relationships to Disclose
 
Mary Weber Redman
No Relationships to Disclose
 
Kathy S. Albain
Honoraria - Encore Medical Education
Research Funding - Quantum Leap Healthcare Collaborative (Inst); Seagen (Inst)
Other Relationship - Seagen
 
Karen Kelly
Patents, Royalties, Other Intellectual Property - Author Royalties for UpToDate, an evidence based, peer reviewed information resource, available via the web, desktop, and PDA.
 
Christine B. Ambrosone
No Relationships to Disclose
 
Jhanelle E. Gray
Honoraria - AstraZeneca; Daiichi Sankyo, Inc; EMD Serono/Merck; Flatiron Health; Gilead Sciences; Gilead Sciences; IDEOlogy Health; Janssen Scientific Affairs; Jazz Pharmaceuticals; Merck; Merck; OncoCyte; Pfizer; Regeneron; Spectrum ODAC; Triptych Health Partners
Consulting or Advisory Role - Abbvie; AstraZeneca; Daiichi Sankyo/UCB Japan; Flatiron Health; Gilead Sciences; Gilead Sciences; IDEOlogy Health; Jazz Pharmaceuticals; Merck; Merck; Pfizer; Regeneron; Spectrum Pharmaceuticals; Triptych Health Partners
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); Gilead Services (Inst); Lilly (Inst); Ludwig Institute for Cancer Research (Inst); Merck (Inst); Novartis (Inst); Panbela Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - Abbvie; OncoCyte; Spectrum Pharmaceuticals
 
Akihito Kubo
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; Novartis; Taiho Pharmaceutical
Research Funding - Boehringer Ingelheim; Chugai Pharma; Ono Pharmaceutical
 
David R. Gandara
Honoraria - Merck
Consulting or Advisory Role - Adagene (Inst); AstraZeneca (Inst); Guardant Health (Inst); Guardant Health (Inst); IO Biotech (Inst); OncoCyte (Inst); OncoHost (Inst); Roche/Genentech (Inst)
Research Funding - Amgen (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Genentech (Inst); Merck (Inst)
 
Primo N Lara
Research Funding - AstraZeneca (Inst); Taiho Pharmaceutical (Inst)
 
Tomoya Kawaguchi
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)